Features

Affected as a young child by a rare disease which targets just one in 200,000 and led to neurodegeneration throughout her teens, Niamh ni Ruari...

Louis Goss examines mental health from a health economics and outcomes research (HEOR) perspective and asks what might be done to improve the way...

Nick Stephens of the RSA Group discusses the importance of stopping to quantify the effectiveness of board members within life sciences, and...

In light of continued austerity gripping the NHS, it was uplifting to hear in July that the health service had generated millions in savings by...

Just as his company announced robust H1 2018 financials, UCB's Jean-Christophe Tellier spoke to Pharmafocus to share his experiences of the tough...

Dr Rachelle Doody, Global Head of Neurodegeneration at Roche/Genentech, discusses key learnings from clinical trials in Alzheimer’s disease, and...

Scottish comedian Carina MacLeod recounts her life with fibromyalgia and the benefits of comedy in dealing with a chronic condition, explaining...

What does Brexit mean for drug safety in Europe and the United Kingdom? Louis Goss looks into Britain’s exit from the European Union and asks what...

Researchers at the University of East Anglia have developed a new targeted cancer therapy which utilises nanoparticles to deliver treatment...

Cancer treatment is making leaps and bounds, but public focus tends to gravitate towards the therapies themselves. Matt Fellows explores other...